Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Challenge to brain injury guideline care

A randomized controlled trial has cast doubt on whether it is necessary to routinely place an intraparenchymal pressure monitor in patients with severe traumatic brain injury.

14 Dec 2012

Fingolimod associated with modest, rapid increase in macular volume

Patients with multiple sclerosis treated with fingolimod undergo a modest but rapid increase in macular volume, research shows.

13 Dec 2012

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.

13 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO).

6 Dec 2012

NICE reject intravitreal implant for diabetic macular edema

The UK National Institute for Health and Clinical Excellence has not recommended a fluocinolone acetonide intravitreal implant for individuals with diabetic macular edema who do not respond to existing therapies.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Combination of ketogenic diet and radiation therapy effectively treats malignant gliomas

A team of brain cancer researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has effectively treated brain tumor cells using a unique combination of diet and radiation therapy.

5 Dec 2012

December issue of Neurosurgical Focus explores sports-related concussions

The JNS Publishing Group is pleased to announce that the December issue of Neurosurgical Focus is dedicated to Concussion: Pathophysiology & Sequelae.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

30 Nov 2012

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision Incorporated today announced that patient enrollment has been completed in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

29 Nov 2012

Brain effects of high-altitude sickness retained long term

Mountaineers who experience high-altitude cerebral edema often retain traces of the bleed in their brains for many years afterward, show study findings.

28 Nov 2012

Brain microhemorrhages more common among high altitude cerebral edema survivors

New magnetic resonance imaging (MRI) research shows that mountain climbers who experience a certain type of high altitude sickness have traces of bleeding in the brain years after the initial incident, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

28 Nov 2012

EC approves Regeneron’s EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).

27 Nov 2012

Meningiomas likely results from hemodynamic changes associated with pregnancy

Meningiomas are a common type of benign brain tumor that sometimes grows dramatically in pregnant women. A new study suggests that this sudden tumor growth likely results from "hemodynamic changes" associated with pregnancy, reports the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

21 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Minor symptoms a big deal in nasal polyposis

Asthma does not have any significant influence on quality of life among patients with nasal polyposis, but it may increase the intensity of individual minor symptoms such as headache, or fullness in the ears, report researchers.

14 Nov 2012

Edema News and Research

Further Reading

Challenge to brain injury guideline care

Fingolimod associated with modest, rapid increase in macular volume

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

NICE reject intravitreal implant for diabetic macular edema

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Combination of ketogenic diet and radiation therapy effectively treats malignant gliomas

December issue of Neurosurgical Focus explores sports-related concussions

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

Brain effects of high-altitude sickness retained long term

Brain microhemorrhages more common among high altitude cerebral edema survivors

EC approves Regeneron’s EYLEA for treatment of wet AMD

Meningiomas likely results from hemodynamic changes associated with pregnancy

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Minor symptoms a big deal in nasal polyposis

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News